Skip to main content

Table 1 Patient Demographics

From: Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma

  All (N = 58) Group 1 (N = 13) Group 2 (N = 35) Group 3 (N = 10)
Median Weight (kg) 30.1 25.2 30.3 33.3
Range (Min, Max) 5, 85 6, 53 6, 85 5, 52
Median Age (yr) 7 7 7 7
Range (Min, Max) 3, 12 4, 12 3, 12 3, 13
Sex
 Female 22 7 11 2
 Male 36 6 23 7
Stage
 II 1 0 1 0
 III 36 7 21 6
 IV 18 5 10 3
 V 3 1 2 0
Immunophenotype
 B-cell (Naïve) 28 9 19 0
 B-cell (Relapsed) 14 2 6 6
 T-cell (Naïve) 7 1 6 0
 T-cell (Relapsed) 7 1 3 3
 Not Determined 2 0 1 1
Corticosteroid Use
 Prior prednisone 15 1 8 6
 Prednisone use after enrollment 25 7 15 3
 No prednisone use 18 5 11 1